Table 1.
Characteristics of patients with mild or moderate and severe COVID-19 among Umrah pilgrims returning to Turkey.
| Patients | Mild or moderate, n (%) 39 (73) | Severe, n (%) 16 (27) | p |
|---|---|---|---|
| Median age (range), years | 59 (12–85) | 66 (45–63) | 0,01 |
| Age ≥65 | 11 (28) | 10 (62,7) | 0,02 |
| Male gender | 15 (38) | 5 (31) | 0,7 |
| Initial symptoms | |||
| Fever | 16 (41) | 12 (75) | 0,02 |
| Cough | 23 (58) | 7 (43) | 1 |
| Dyspnea | 10 (25) | 2 (12) | 0,1 |
| Sore throat | 16 (41) | 2 (12) | 0,5 |
| Myalgia | 15 (38) | 10 (62) | 0,01 |
| Fatigue | 28 (71) | 11 (68) | 0,7 |
| Nausea and vomiting | 7 (18) | 2 (12) | 0,7 |
| Diarrhea | 7 (18) | 3 (18) | 0,4 |
| Comorbidities | |||
| Hypertension | 15 (38)) | 6 (37) | 1 |
| Diabetes | 10 (25) | 2 (12) | 0,4 |
| Cardiovascular disease | 1 (2) | 2 (12) | 0,2 |
| Chronic Obstructive Pulmonary Disease | 5 (12) | 3 (18) | 0,4 |
| Laboratory findings | |||
| White blood cells,/μL | 5990 (3520–12900) | 6380 (3250–16700) | 0,5 |
| Neutrophils,/μL | 3770 (1190–14300) | 4235 (1890–14300) | 0,3 |
| Lymphocytes, μL | 1900 (890–5340) | 1540 (840–2100) | 0,04 |
| Hemoglobin (g/dL), | 14,7 ± 1,2 | 13,9 ± 1,1 | 0,1 |
| Platelet count, x10³μL | 216 (142–466) | 188 (98–389) | 0,2 |
| AST, IU | 23 (8–84) | 25 (13–194) | 0,5 |
| ALT, IU | 20 (5–63) | 20 (11–166) | 0,3 |
| Lactate dehydrogenase, U/L | 210 ± 32 | 282 ± 24 | 0,09 |
| Empirical treatmenta | |||
| Oseltamivir | 36 (92) | 15 (93) | 0,8 |
| Hydroxychloroquine | 35 (89) | 14 (87) | 0,08 |
| Clarithromycin | 34 (87) | 15 (93) | 0,6 |
| Ceftriaxone | 3 (7) | 8 (50) | 0,01 |
a
Oseltamivir (75 mg every 12 hours for five days), Hydroxychloroquine (loading dose of 800 mg followed by 400 mg for five days), Clarithromycin (1g/day for 10–14 days), Ceftriaxone (1gr, every 12 hours).